Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0254367 http://scihub22266oqcxt.onion/10.1371/journal.pone.0254367 34242356!8270414!34242356     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+One 2021 ; 16 (7): e0254367 Nephropedia Template TP {{tp|p=34242356|t=2021. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses |pdf=|usr=}}{{34242356}} gab.com Text Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=34242356 #FOAvip COVID-19 serological test must have high sensitivity as well as specificity to rule out cross-reactivity with common coronaviruses (HCoVs). We have developed a quantitative multiplex test, measuring antibodies against spike (S) proteins of SARS-CoV-2, SARS-CoV, MERS-CoV, and common human coronavirus strains (229E, NL63, OC43, HKU1), and nucleocapsid (N) protein of SARS-CoV viruses. Receptor binding domain of S protein of SARS-CoV-2 (S-RBD), and N protein, demonstrated sensitivity (94% and 92.5%, respectively) in COVID-19 patients (n = 53), with 98% specificity in non-COVID-19 respiratory-disease (n = 98), and healthy-controls (n = 129). Anti S-RBD and N antibodies appeared five to ten days post-onset of symptoms, peaking at approximately four weeks. The appearance of IgG and IgM coincided while IgG subtypes, IgG1 and IgG3 appeared soon after the total IgG; IgG2 and IgG4 remained undetectable. Several inflammatory cytokines/chemokines were found to be elevated in many COVID-19 patients (e.g., Eotaxin, Gro-alpha, CXCL-10 (IP-10), RANTES (CCL5), IL-2Ralpha, MCP-1, and SCGF-b); CXCL-10 was elevated in all. In contrast to antibody titers, levels of CXCL-10 decreased with the improvement in patient health suggesting it as a candidate for disease resolution. Importantly, anti-N antibodies appear before S-RBD and differentiate between vaccinated and infected people-current vaccines (and several in the pipeline) are S protein-based. Twit Text FOAVip Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=34242356 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34242356 #FOAvip English Wikipedia <ref>{{Cite pmid|34242356}}</ref> Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses #MMPMID34242356 Ravindran R; McReynolds C; Yang J; Hammock BD; Ikram A; Ali A; Bashir A; Zohra T; Chang WLW; Hartigan-O'Connor DJ; Rashidi HH; Khan IH PLoS One 2021[]; 16 (7): e0254367 PMID34242356show ga COVID-19 serological test must have high sensitivity as well as specificity to rule out cross-reactivity with common coronaviruses (HCoVs). We have developed a quantitative multiplex test, measuring antibodies against spike (S) proteins of SARS-CoV-2, SARS-CoV, MERS-CoV, and common human coronavirus strains (229E, NL63, OC43, HKU1), and nucleocapsid (N) protein of SARS-CoV viruses. Receptor binding domain of S protein of SARS-CoV-2 (S-RBD), and N protein, demonstrated sensitivity (94% and 92.5%, respectively) in COVID-19 patients (n = 53), with 98% specificity in non-COVID-19 respiratory-disease (n = 98), and healthy-controls (n = 129). Anti S-RBD and N antibodies appeared five to ten days post-onset of symptoms, peaking at approximately four weeks. The appearance of IgG and IgM coincided while IgG subtypes, IgG1 and IgG3 appeared soon after the total IgG; IgG2 and IgG4 remained undetectable. Several inflammatory cytokines/chemokines were found to be elevated in many COVID-19 patients (e.g., Eotaxin, Gro-alpha, CXCL-10 (IP-10), RANTES (CCL5), IL-2Ralpha, MCP-1, and SCGF-b); CXCL-10 was elevated in all. In contrast to antibody titers, levels of CXCL-10 decreased with the improvement in patient health suggesting it as a candidate for disease resolution. Importantly, anti-N antibodies appear before S-RBD and differentiate between vaccinated and infected people-current vaccines (and several in the pipeline) are S protein-based. |*Antibodies, Viral/blood/immunology[MESH] |*COVID-19/blood/immunology[MESH] |*Chemokines/blood/immunology[MESH] |*Coronavirus Nucleocapsid Proteins/blood/immunology[MESH] |*Immunoglobulin G/blood/immunology[MESH] |*Immunoglobulin M/blood/immunology[MESH] |*SARS-CoV-2/immunology/metabolism[MESH] |*Spike Glycoprotein, Coronavirus/blood/immunology[MESH] |Adult[MESH] |Animals[MESH] |Female[MESH] |Humans[MESH] |Macaca mulatta[MESH] |Male[MESH] |Middle Aged[MESH] |Phosphoproteins/blood/immunology[MESH]Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other (epmc).pdf DeepDyve Pubget Overpricing